The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study Article

Industry Collaboration International Collaboration

author list

  • Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D. J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A. B.; Guttman-Yassky, E.

publication date

  • October 1, 2019


published in


start page

  • 733

end page

  • 742


  • 181


  • 4